source
- Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drugAvalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public…Endpoints · 3mo ago↗ source
- Novartis pulls Pluvicto prostate cancer label expansion filing in the EUNovartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain fav…Endpoints · 3mo ago↗ source
- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelicsLilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.